

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : AMXT-1501 dicaprate,Eflornithine Hydrochloride,Fulvestrant,Capivasertib,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
Details : AMXT 1501 Dicaprate is a small molecule drug candidate, which is currently being evaluated in Phase I/ Phase II clinical studies for the treatment of Melanoma.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 17, 2025
Lead Product(s) : AMXT-1501 dicaprate,Eflornithine Hydrochloride,Fulvestrant,Capivasertib,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
